A Pilot Study of Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Acalabrutinib (Primary) ; Bendamustine; Cytarabine; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 30 Nov 2018 Planned End Date changed from 31 Dec 2025 to 30 Nov 2025.
- 30 Nov 2018 Planned primary completion date changed from 30 Jun 2021 to 31 May 2021.
- 30 Nov 2018 Status changed from not yet recruiting to recruiting.